Targeted disruption of PRC1.1 complex enhances bone remodeling.

Area of Science:

• Epigenetics
• Bone Biology
• Molecular Medicine

Background:

• Polycomb repressive complexes (PRCs) are key epigenetic regulators maintaining cell identity.
• The specific roles of PRCs, particularly PRC1.1, in osteoblast function and bone formation are not well understood.
• Aging is associated with altered epigenetic landscapes, potentially impacting bone health.

Purpose of the Study:

• To investigate the role of PRC1.1 in osteoblast function and bone formation.
• To identify the molecular mechanisms by which PRC1.1 influences bone remodeling.
• To explore therapeutic strategies targeting PRC1.1 for bone loss conditions.

Main Methods:

• Analysis of PRC1.1 activation in aging osteoblasts.
• Chromatin immunoprecipitation to identify PRC1.1 binding factors (KDM2B, BCOR, PCGF1).
• Generation of osteoblast-specific Kdm2b knockout mice.
• Development of a small molecule inhibitor (iBP) targeting PRC1.1.
• Assessment of bone remodeling and Wnt signaling in mouse models.

Main Results:

• PRC1.1 is activated in aging osteoblasts, with KDM2B, BCOR, and PCGF1 mediating H2A monoubiquitylation (H2AK119ub1).
• Osteoblast-specific Kdm2b inactivation promotes bone remodeling by downregulating H2AK119ub1 and activating Wnt signaling.
• The small molecule iBP effectively inhibits PRC1.1 activity.
• iBP administration enhances bone formation in mouse models of bone loss.

Conclusions:

• PRC1.1 acts as a critical epigenetic brake on bone formation.
• Targeting PRC1.1, via inhibition of BCOR-PCGF1 interaction, enhances Wnt pathway activation.
• Therapeutic inhibition of PRC1.1 presents a promising strategy for combating skeletal deterioration and bone loss.